Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Takeda has been eyeing India’s vaccine market since at least 2015, and the idea has come to fruition in the form of two licensing deals.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.
GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.